Brief: China Medical System Entered Into Two Separate Exclusive Collaboration Agreements
Sept 22 (Reuters) - China Medical System Holdings Ltd 0867.HK: ENTERED INTO TWO SEPARATE EXCLUSIVE COLLABORATION AGREEMENTS WITH CHONGQING GENRIX BIOPHARMACEUTICAL UNDER DEALS, OBTAINED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR VECANTOXATUG AND SILEVIMIG INJECTIONS IN MAINLAND CHINA, OTHERS Further company coverage: 0867.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says